Onco-Innovations and Redwood AI Partner to Accelerate Preclinical Development of PNKP Inhibitor for Solid Tumor Therapies

Onco-Innovations Partners with Redwood AI to Enhance PNKP Inhibitor Development

Onco-Innovations (OTCQB:ONNVF) has signed a services agreement with Redwood AI to advance its Polynucleotide Kinase Phosphatase (PNKP) compound technology. This collaboration integrates Redwood AI's artificial intelligence-driven chemistry tools to improve Onco's drug development process, focusing on synthesis evaluation, cheminformatics, and organ-specific toxicity prediction.

The PNKP compound targets solid tumors by increasing their sensitivity to radiation and DNA-damaging chemotherapies. The partnership aims to boost scalability, safety, and precision in drug discovery as Onco moves towards initiating First-in-Human clinical trials.

What This Means for Drug Development

By leveraging Redwood AI’s technology, Onco-Innovations gains access to advanced in-silico modeling and independent reviews of chemistry proposals. This support helps refine compound design, reduce synthesis complexity, and expand the pipeline of viable analogs—all critical during the preclinical phase.

Redwood AI specializes in automating drug synthesis steps that are traditionally manual and time-consuming. Their platform is built to help teams accelerate the transition from discovery to development, potentially reducing both timelines and costs.

Strategic Benefits and Challenges

• Benefits: Access to AI-driven tools for synthesis and toxicity prediction can improve development speed and compound safety.
• Challenges: The PNKP technology is still in preclinical stages with no immediate revenue. The effectiveness of AI integration in this context has yet to be fully demonstrated.

About Onco-Innovations

Onco-Innovations is a Canadian company focused on cancer research, holding exclusive global rights to the PNKP compound technology. Its mission is to develop new treatments targeting solid tumors by increasing their vulnerability to existing therapies.

About Redwood AI

Based in Vancouver, Redwood AI applies artificial intelligence to streamline drug synthesis. Their team combines expertise in chemistry, AI, and drug manufacturing to address challenges in pharmaceutical development through automation and predictive modeling.

Key Quote

Thomas O'Shaughnessy, CEO of Onco-Innovations: "Redwood AI's platform allows us to explore synthesis strategies and optimize compound design with greater speed and precision. This insight supports faster progress toward clinical trials."

Additional Information

For IT and development professionals interested in AI applications in drug development, this partnership highlights practical uses of AI in chemical synthesis and safety prediction, showcasing how automation and data-driven tools can improve efficiency in biotech R&D.

Learn more about AI-driven drug discovery and development tools at Complete AI Training’s AI tools section.